Despite Celgene Corp.'s low expectations regarding Revlimid's ability as a monotherapy in the difficult indication of metastatic malignant melanoma patients who already had failed two lines of therapy, the firm's stock dipped on stopping a Phase III trial in that indication. (BioWorld Today)
ChemGenex Therapeutics Inc. and AGT Biosciences Ltd. are merging to form a genomics-driven pharmaceutical firm with leading-edge technology and two cancer drugs in clinical trials, officials from both companies said. (BioWorld Today)
ChemGenex Therapeutics Inc. and AGT Biosciences Ltd. are merging to form a genomics-driven pharmaceutical firm with leading-edge technology and two cancer drugs in clinical trials, officials from both companies said. (BioWorld Today)
